Today: 30 June 2026
Opendoor stock today: Shares slide to $6 as traders brace for housing data and Fed minutes

Opendoor stock today: Shares slide to $6 as traders brace for housing data and Fed minutes

NEW YORK, December 29, 2025, 02:33 ET — Market closed

  • Opendoor shares last closed down 4.3% at $6.01 on Friday.
  • U.S. pending home sales data due at 10 a.m. ET Monday puts housing-related stocks in focus.
  • Fed meeting minutes on Tuesday are the next big test for rate-cut expectations into 2026.

Opendoor Technologies Inc shares closed down 4.3% at $6.01 on Friday, their latest available finish ahead of Monday’s reopening in U.S. equities.

The move matters now because investors head into the final sessions of 2025 with interest-rate expectations back in the driver’s seat, a key swing factor for housing demand and housing-linked stocks.

A fresh read on U.S. housing demand arrives Monday when the National Association of Realtors releases its pending home sales index for November at 10 a.m. ET.

Opendoor, which buys and sells homes online, tends to trade as a high-beta proxy for housing sentiment because its business is exposed to home prices, demand and financing conditions.

Pending home sales track signed contracts to buy existing homes, making it a forward-looking gauge for closings a month or two later.

The stock traded between $5.98 and $6.24 on Friday and saw about 47.3 million shares change hands, according to the company’s stock quote data.

Market participants are also bracing for the distortions that come with year-end positioning and light volumes, which can exaggerate price swings, a Reuters report on the week ahead noted.

“Handicapping how many rate cuts we’re going to get next year is a big thing markets are focused on right now,” Michael Reynolds, vice president of investment strategy at Glenmede, said in that report. Reuters

In the broader housing trade, iBuyer rival Offerpad Solutions closed down 4.5% on Friday at $1.28, while mortgage lender Rocket Companies finished little changed at $19.44.

Traders will also watch Tuesday’s Fed minutes for details of the December meeting debate, and the S&P Case-Shiller home price index the same day for another read on housing conditions.

Before the next session, the first key timestamp is Monday’s 10 a.m. ET pending home sales release, which can move mortgage-sensitive names if it shifts expectations for spring demand.

Tuesday’s Fed minutes are the week’s main policy catalyst; investors will look for clues on how officials weighed inflation and growth as markets debate the pace of 2026 rate cuts.

Opendoor’s next quarterly results are expected on Feb. 26, according to Zacks Investment Research, leaving macro and rates as the main near-term drivers for the stock.

From a tape-watching standpoint, traders have focused on whether the stock holds the $6 level after Friday’s dip to $5.98, with $6.28 — the prior close — a nearby marker overhead.

Sources: Opendoor price data; National Association of Realtors release schedule; Reuters week-ahead markets report; Investopedia economic calendar.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • SELLAS Life Sciences (NASDAQ:SLS) Drops 7.77% After 8-K Filing Ahead of REGAL Data
    June 30, 2026, 10:28 AM EDT. SELLAS Life Sciences shares dropped 7.77% to $14.25 on Tuesday after an 8-K showing senior management agreements and as the market waits for Phase 3 REGAL data on galinpepimut-S in AML. The study is approaching a milestone with 78 of 80 survival events, making some investors cautious. The stock recently hit a 52-week high of $15.67, but resistance is holding there with support at the 20-day simple moving average around $8.87. Technicals are flashing overbought with the RSI at 85.19, which could mean sharper pullbacks. SELLAS works on cancer therapies including GPS and CDK9 drugs, tying its shares to updates around leadership moves and clinical trials.
HFCL jumps 10% on heavy volumes even as MarketsMojo keeps “Strong Sell” callNEW YORK, December 29, 2025, 00:11 ET
Previous Story

HFCL jumps 10% on heavy volumes even as MarketsMojo keeps “Strong Sell” callNEW YORK, December 29, 2025, 00:11 ET

Tesla stock slips as supplier guts $2.9 bln battery deal to $7,386
Next Story

Tesla stock slips as supplier guts $2.9 bln battery deal to $7,386

Go toTop